Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)
Yimin Liu, Jing‐Ping Liou
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 5, pp. 349-369
Closed Access | Times Cited: 13

Showing 13 citing articles:

Discovery of novel anticancer flavonoids as potential HDAC2 inhibitors: virtual screening approach based on molecular docking, DFT and molecular dynamics simulations studies
Ashish Shah, Aarti Choudhary, Manav Jain, et al.
3 Biotech (2024) Vol. 14, Iss. 3
Closed Access | Times Cited: 15
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 18
Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy
Osama M. Soltan, Kamal S. Abdelrahman, Amr K.A. Bass, et al.
Bioorganic Chemistry (2024) Vol. 151, pp. 107651-107651
Closed Access | Times Cited: 5
Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function
Yuheng Jin, Xuxin Qi, Xiaoli Yu, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
HAT1/HDAC2 mediated ACSL4 acetylation confers radiosensitivity by inducing ferroptosis in nasopharyngeal carcinoma
Peijun Zhou, Xingzhi Peng, Kun Zhang, et al.
Cell Death and Disease (2025) Vol. 16, Iss. 1
Open Access
Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess
Tsung‐Cheng Yin, Yuyu Liu, Chenwen Li, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency
Yuan Jiang Pan, Haodong Hou, Bo Zhou, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115879-115879
Closed Access | Times Cited: 8
Enhancement of physiology via adaptive transcription
Thomas Lissek
Pflügers Archiv - European Journal of Physiology (2024)
Open Access | Times Cited: 1
Chromatin Remodeling-Related PRDM1 Increases Stomach Cancer Proliferation and Is Counteracted by Bromodomain Inhibitor
Yu‐Hsuan Hung, Hui‐Ching Wang, Mei‐Ren Pan, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 3, pp. 224-224
Open Access
Potential to use of viral reverse transcriptase inhibitors in oncology
Olga Vlasova, Irina Antonova, Kh. M. Magomedova, et al.
Advances in molecular oncology (2024) Vol. 11, Iss. 2, pp. 8-28
Closed Access
Therapeutic indications for HDAC6 inhibitors in the peripheral and central nervous disorders
Jonathan van Eyll, Robert Prior, Sylvain Célanire, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 9, pp. 719-737
Closed Access
Unlocking Macrophage Secrets: Histone Deacetylases in Chronic Transplant Rejection
Marta Hałasa, Anna Wawruszak
Results and problems in cell differentiation (2024), pp. 297-313
Closed Access
Anti-Colorectal Cancer Activity of Solasonin from Solanum nigrum L. via Histone Deacetylases-Mediated p53 Acetylation Pathway
Xintian Lan, Meng Lu, Xiaoxue Fang, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6649-6649
Open Access
Page 1

Scroll to top